GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GSK PLC (NYSE:GSK) » Definitions » NonCurrent Deferred Liabilities

GSK (GSK) NonCurrent Deferred Liabilities : $0 Mil (As of Dec. 2023)


View and export this data going back to 1987. Start your Free Trial

What is GSK NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

GSK's non-current deferred liabilities for the quarter that ended in Dec. 2023 was $0 Mil.

GSK NonCurrent Deferred Liabilities Historical Data

The historical data trend for GSK's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GSK NonCurrent Deferred Liabilities Chart

GSK Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

GSK Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

GSK NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of GSK's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


GSK (GSK) Business Description

Industry
Address
980 Great West Road, Brentford, Middlesex, GBR, TW8 9GS
In the pharmaceutical industry, GSK ranks as one of the largest companies by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

GSK (GSK) Headlines

From GuruFocus

Top 5 4th Quarter Trades of JTC Employer Solutions Trustee Ltd

By GuruFocus Research GuruFocus Editor 01-18-2023

Top 5 4th Quarter Trades of HealthInvest Partners AB

By GuruFocus Research GuruFocus Editor 02-18-2023

GSK: Undervalued at Peak Pessimism

By Nathan Aisenstadt 11-19-2023

Kahn Brothers Buys 1, Sells 4 in 4th Quarter

By GuruFocus Research GuruFocus Editor 02-15-2023

GSK Enters Agreement to Acquire Aiolos Bio

By Business Wire 01-09-2024

GSK: Step-Changing for Growth

By Pavaki Capital 11-16-2022

Ridgewood Investments LLC Buys 3, Sells 2 in 4th Quarter

By GuruFocus Research GuruFocus Editor 01-20-2023